Zepbound (Tirzepatide) for Weight Management
Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist indicated for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, administered as a once-weekly subcutaneous injection starting at 2.5 mg and escalating to maintenance doses of 5,10, or 15 mg. 1, 2
Indications
Tirzepatide is approved for:
- Chronic weight management in adults with:
- BMI ≥30 kg/m² (obesity), OR
- BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
- Type 2 diabetes mellitus (as Mounjaro, not Zepbound)
Critical positioning consideration: For patients with obesity at moderate-to-high cardiovascular or kidney risk, tirzepatide should NOT replace medications with proven cardiovascular/kidney benefits (SGLT-2 inhibitors or GLP-1 receptor agonists). If switching from a GLP-1 RA to tirzepatide for superior weight loss, you must initiate or continue an SGLT-2 inhibitor. 1
Dosing Regimen
Escalation schedule (all doses once weekly, subcutaneous):
- Weeks 1-4: 2.5 mg (starting dose, not therapeutic)
- Weeks 5-8: 5 mg (first maintenance dose)
- Weeks 9-12: 10 mg (if additional weight loss needed and tolerated)
- Week 13+: 15 mg (maximum dose, if needed and tolerated)
Key dosing principles:
- Allow 4 weeks between dose escalations to minimize gastrointestinal adverse effects 2
- The 2.5 mg dose is for initial tolerability only—not a therapeutic maintenance dose
- Recent evidence suggests 2.5 mg may provide comparable efficacy to 5 mg in some populations with better tolerability, though this is not standard practice 3
- Maximum tolerated dose should be used for optimal weight reduction 4
Expected Efficacy
Weight loss outcomes (at 72 weeks in non-diabetic adults with obesity):
- 5 mg: Mean 15.0% body weight loss; 85% achieve ≥5% loss 5
- 10 mg: Mean 19.5% body weight loss; 89% achieve ≥5% loss, 50% achieve ≥20% loss 5
- 15 mg: Mean 20.9% body weight loss; 91% achieve ≥5% loss, 57% achieve ≥20% loss 5
In type 2 diabetes patients, weight loss is somewhat attenuated (6-10 kg depending on dose) but still clinically significant 6, 7. Tirzepatide produces superior weight loss compared to semaglutide 1.0 mg weekly 8.
Contraindications
Absolute contraindications:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Prior serious hypersensitivity to tirzepatide
Do NOT combine with:
- GLP-1 receptor agonists (redundant mechanism, increased adverse effects without added benefit) 1
Can be combined with:
- SGLT-2 inhibitors (recommended for high-risk patients)
- Finerenone
- Metformin
Adverse Effects
Most common (gastrointestinal, dose-dependent):
- Nausea: Most frequent, occurs primarily during dose escalation 9
- Diarrhea: Second most common GI effect 9
- Vomiting: Dose-related 9
- Constipation: Less common than nausea/diarrhea 9
- Decreased appetite: Expected pharmacologic effect 2
Incidence of GI adverse events:
- 5 mg: 39%
- 10 mg: 46%
- 15 mg: 49% 9
These are generally mild-to-moderate and transient, occurring primarily during dose escalation. The 4-week escalation intervals are designed to minimize these effects.
Treatment discontinuation due to adverse events:
- 5 mg: 4.3%
- 10 mg: 7.1%
- 15 mg: 6.2% (highest dose has paradoxically lower discontinuation than 10 mg in some studies) 5
- Overall: ~10% at 15 mg dose 9
Serious but rare adverse effects (≤1% incidence):
- Acute pancreatitis 9
- Cholelithiasis/cholecystitis (gallstone-related complications) 2, 9
- Severe gastrointestinal events (small bowel obstruction/ileus) 2
- Severe hypoglycemia (extremely rare without concomitant insulin or sulfonylurea) 9
Mild hypoglycemia (glucose <70 mg/dL):
- Highest with 10 mg dose: 22.6% 9
- Clinically significant only when combined with insulin or sulfonylureas
Other considerations:
- May cause elevated heart rate 2
- Injection site reactions possible 2
- Delayed gastric emptying may affect absorption of oral medications with narrow therapeutic index 2
- Oral contraceptive users: Switch to non-oral contraceptive method or add barrier method for 4 weeks after initiation and 4 weeks after each dose escalation 2
Cardiovascular Safety
Current evidence shows cardiovascular safety but NOT proven benefit:
- Meta-analysis of SURPASS trials: No cardiovascular event had hazard ratio >1.0 vs. comparators 8
- Upper confidence interval bounds for MACE <1.3 (meets conventional cardiovascular safety criteria) 8
- MACE-4 events trended toward reduction over 2 years, but with low event numbers 8
- Critical distinction: Unlike GLP-1 RAs (semaglutide, liraglutide), tirzepatide does NOT yet have proven cardiovascular outcome benefits—only demonstrated safety 1
This is why guidelines recommend NOT replacing proven cardiovascular medications with tirzepatide in high-risk patients.
Clinical Decision-Making Algorithm
For patients with obesity and LOW cardiovascular/kidney risk:
- Tirzepatide is preferred over GLP-1 RAs due to superior weight loss 1
For patients with obesity and MODERATE-to-HIGH cardiovascular/kidney risk:
- First-line: SGLT-2 inhibitor AND/OR GLP-1 RA (proven cardiovascular/kidney benefits)
- If prioritizing weight loss: May add or switch to tirzepatide BUT must ensure SGLT-2 inhibitor is initiated/continued 1
- Never: Replace SGLT-2 inhibitor or GLP-1 RA with tirzepatide alone in high-risk patients
For patients with type 2 diabetes:
- Tirzepatide produces superior glycemic control (HbA1c reductions of 1.87-2.58%) and 23-62% achieve normoglycemia (HbA1c <5.7%) 8, 4
- Same cardiovascular risk stratification applies as above
Practical Monitoring
- Monitor for gastrointestinal symptoms, especially during first 4 weeks of each new dose
- Assess for signs/symptoms of pancreatitis (severe abdominal pain)
- Monitor for gallbladder disease symptoms
- Check blood glucose if on concomitant diabetes medications
- Reassess oral contraceptive efficacy during dose escalation periods
Cost Considerations
Monthly cost (30-day supply at maintenance dose): $1,272 (AWP) or $1,017 (NADAC) 2. This is comparable to semaglutide 2.4 mg but substantially higher than older weight management medications.